Literature DB >> 3337049

The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer.

A M Shojania1, J Tetreault, G Turnbull.   

Abstract

The variations between different lots of activated partial thromboplastin time (APTT) produced by three major North American suppliers were evaluated over the past eight years. The authors found significant variations between the heparin sensitivity of the APTT reagents produced under the same name by the same supplier. The variations were so much that, using the recommended APTT ratio or prolongation of APTT for monitoring heparin therapy, one would have achieved significantly different intensity of heparinization from year to year.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337049     DOI: 10.1093/ajcp/89.1.19

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.

Authors:  S Kitchen; I Jennings; T A Woods; F E Preston
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

Review 3.  Control of anticoagulant and antiplatelet therapy. Managing patients with acute thrombotic disorders.

Authors:  D R Anderson; L A Fernandez
Journal:  Can Fam Physician       Date:  1993-02       Impact factor: 3.275

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

5.  The effect of oral anticoagulant therapy on APTT results from a bedside coagulation monitor.

Authors:  M J Ray; P A Carroll; S J Just; G A Hawson; J H Bett
Journal:  J Clin Monit       Date:  1994-03

6.  Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.

Authors:  M Cullberg; U G Eriksson; M Larsson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

7.  Establishing a new target range for unfractionated heparin for acute coronary syndromes.

Authors:  Michael S Lee; Venu Menon; Joseph Schappert; James R Wilentz; Varinder Singh; Judith S Hochman
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

Review 8.  Hemostatic complications in renal disorders of the young.

Authors:  M Andrew; L A Brooker
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

Review 9.  "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.

Authors:  Vittorio Pavoni; Lara Gianesello; Duccio Conti; Piercarlo Ballo; Pietro Dattolo; Domenico Prisco; Klaus Görlinger
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

Review 10.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.